Supplements to Fall Asleep Faster

A grey-market research peptide whose human evidence is a handful of small, old, and equivocal studies — and no modern, adequately-powered trial. DSIP (delta sleep-inducing peptide) is a nine-amino-acid neuropeptide named in the 1970s for inducing delta (slow-wave) EEG activity. Small 1980s studies in severe insomnia (some open-label, some double-blind placebo-controlled) reported improved sleep, but the positive controlled trials were tiny and mostly from a single investigator, while an independent double-blind crossover trial concluded any sleep benefit was 'of little clinical significance.' A later randomized anaesthesia study found DSIP paradoxically lightened — not deepened — anaesthetic depth and reduced delta rhythm. Most newer data is from rats. DSIP is not an approved drug or a lawful dietary supplement; it is sold online as an unregulated injectable research chemical with unknown long-term safety. This entry exists to inform, not to recommend.

A GABA-B receptor agonist — β-phenyl-GABA — developed in the USSR and still prescribed there as an anxiolytic and nootropic (brands Anvifen, Fenibut, Noofen). It is NOT approved in the US, UK or EU, where it is sold online as a 'nootropic' or anxiolytic 'supplement' and used recreationally for anxiety, sleep and sociability. A genuine but mostly Russian, limited clinical literature supports its anxiolytic use; the DOMINANT Western literature, however, is case reports of DEPENDENCE, rapid TOLERANCE, and severe WITHDRAWAL — agitation, insomnia, psychosis, delirium and seizures resembling baclofen or alcohol/benzodiazepine withdrawal — plus OVERDOSE/toxicity with reduced consciousness requiring intensive care. Phenibut is dangerous combined with alcohol or other CNS depressants. Frame: a real GABA-B anxiolytic carrying a serious dependence and withdrawal risk and almost no Western regulatory standing. Informational, harm-reduction entry only — not a recommendation.